Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-28
2010-12-14
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07851470
ABSTRACT:
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
REFERENCES:
patent: 3868380 (1975-02-01), Molteni et al.
patent: 6538960 (2003-03-01), Sabi et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 7300931 (2007-11-01), Hangauer, Jr.
patent: 2004/0242572 (2004-12-01), Stenkamp et al.
patent: 2005/0059713 (2005-03-01), Mjalli et al.
patent: 2006/0160800 (2006-07-01), Hangauer, Jr.
patent: 2007/0015752 (2007-01-01), Hangauer, Jr.
patent: 2007/0197783 (2007-08-01), Hangauer, Jr.
patent: 0 463 638 (1992-01-01), None
patent: WO 96/12473 (1996-05-01), None
patent: WO 99/01127 (1999-01-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 02/079197 (2002-10-01), None
patent: WO 03/059903 (2003-07-01), None
patent: WO 03/078404 (2003-09-01), None
patent: WO 03/087057 (2003-10-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/011427 (2004-02-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2005/013914 (2005-02-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2006/071960 (2006-07-01), None
patent: WO 2007/026920 (2007-03-01), None
Cain et al., “Potential Antitumor Agents. IX. Bisquaternary Salts”,J. Med. Chem., 11(5):963-966 (1968).
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”,Biochemistry, 43:11658-11671 (2004).
Duong et al., “Inhibition of osteoclast function by adenovirus expressing Antisense protein-tyrosine kinase 2”,J. Biol. Chem., 276(10):7484-7492 (2001).
Frame, M.C., “Src in cancer:deregulation and consequences for cell behaviour”,Biochem. Biophys. Acta, 1602:114-130 (2002).
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”,Science, 286:531-537 (1999).
Guo et al., “Tyrosine phosphorylation of the NR2B subunit of the NMDA receptor in the spinal cord during the development and maintenance of inflammatory hyperalgesia”,J. Neurosci., 22(14):6208-6217 (2002).
Hadjeri et al., “Antimitotic activity of 5-hydroxy-7-methoxy-2-phenyl-4-quinolones”.J. Med. Chem., 47:4964-4970 (2004).
Huff, J.R., “HIV Protease: A Novel Chemotherapeutic Target for AIDS”,J. Med. Chem., 34(8):2305-2314 (1991).
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors”,Cancer Metastasis Rev., 17(1):91-106 (1998).
Liechti et al., “Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor”,Eur. J. Med. Chem., 39(1):11-26 (2004).
Million et al., “Inhibition of the EGF-stimulated cellular proliferation of ER 22 cells by hydroxybiphenyl derivatives”,J. Med. Chem., 38(23):4693-4703 (1995).
Miyazaki et al., “Src kinase activity is essential for osteoclast function”,J. Biol. Chem., 279(17):17660-17666 (2004).
Parang et al., “Recent advances in the discovery of Src kinase inhibitors”,Expert Opin. Ther. Patents, 15(9):1183-1207 (2005).
Paul et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”,Nat. Med., 7(2):222-227 (2001).
Rouhi, A.M., “The right stuff: From research and development to the clinic, getting drug crystals right is full of pitfalls”,Chem. Eng. News, pp. 32-35 (2003).
U.S. Pharmacopia #23, National Formulary #18, pp. 1843-1844 (1995).
Yu et al., “Src, a molecular switch governing gain control of synaptic transmission mediated by N-methyl-D-aspartate receptors”, Proc. Natl. Acad. Sci. USA, 96:7697-7704 (1999).
Zhang et al., “Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs”,Bioorg. Med. Chem. Lett., 14(4):983-987 (2004).
Cody Jeremy A.
Coughlin Daniel
Gale Jonathan
Hangauer, Jr. David G.
Patra Debasis
Elrifi Ivor R.
Erlacher Heidi A.
Henley, III Raymond J
Kinex Pharmaceuticals, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Composition and methods for modulating a kinase cascade does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and methods for modulating a kinase cascade, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and methods for modulating a kinase cascade will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190844